Acorda Therapeutics, Inc. (ACOR) revealed the resubmission of its New Drug Application, or NDA, for Fampridine-SR to the U.S. Food and Drug Administration.
Fampridine-SR is a novel therapy being developed to improve walking ability in people with multiple sclerosis.
Acorda received a Refuse to File letter for the Fampridine-SR NDA on March 30, 2009, which cited the need to correct "format issues" and requested additional supporting information before the NDA could be accepted for review.
Based on subsequent discussions with the FDA, Acorda has resubmitted the Fampridine-SR NDA and believes that all of the Agency's comments related to the RTF have been addressed.
For comments and feedback: editorial@rttnews.com